首页> 外文OA文献 >Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

【2h】

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

机译：精密医学期II研究评估Durvalumab和Tremetimalab与Olaparib在同源复合修复基因突变的患者患者中的双重免疫疗法的疗效评估在Olaparib治疗后响应或稳定的同源复合修复基因突变的患者中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Jean-David Fumet; Emeric Limagne; Marion Thibaudin; Caroline Truntzer; Aurélie Bertaut; Emilie Rederstorff; Francois Ghiringhelli;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment [J] . Jean-David Fumet, Emeric Limagne, Marion Thibaudin, BMC Cancer . 2020,第1期

机译：精密医学期II研究评估Durvalumab和Tremetimalab与Olaparib在同源复合修复基因突变的患者患者中的双重免疫疗法的疗效评估在Olaparib治疗后响应或稳定的同源复合修复基因突变的患者中
2. 318?Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007 [J] . Timothy A Yap, Mallika Dhawan, Andrew E Hendifar, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：318？Olaparib Plus Pembrolizumab患者以前治疗的先进固体肿瘤，具有同源重组修复突变和/或同源重组修复缺陷：KEYLYNK-007
3. ReOL - OLaparib in the REal World. A retrospective observational study to evaluate the impact of olaparib on the real-world treatment of BRCA carrier patients with recurrent ovarian cancer [J] . De Matteis E., Cormio G., Naglieri E., European journal of gynaecological oncology . 2019,第5期

机译：雷尔 - 奥拉帕里布在现实世界中。回顾性观察研究，评价奥拉帕里布对特性卵巢癌的BRCA载体患者的实际处理影响
4. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment [O] . Jean-David Fumet, Emeric Limagne, Marion Thibaudin, 2020

机译：精密医学期II研究评估Durvalumab和Tremetimalab与Olaparib在同源复合修复基因突变的患者患者中的双重免疫疗法的疗效评估在Olaparib治疗后响应或稳定的同源复合修复基因突变的患者中
5. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in - or -mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial [O] . 2016

机译：I期，然后是两个周期的卡铂-olaparib联合olaparib单药疗法与卡培他滨联合HER2阴性或突变的HER2阴性晚期乳腺癌作为一线治疗（REVIVAL）的随机II期试验：一项随机对照试验的研究方案

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

著录项

相似文献

相关主题

期刊订阅